Development of macrolide resistance by ribosomal protein L4 mutation in Streptococcus pyogenes during miocamycin treatment of an eight-year-old Greek child with tonsillopharyngitis.
Streptococcus pyogenes isolates with the same pulsed-field patterns were recovered from the throat cultures of a child with tonsillopharyngitis before and after treatment with miocamycin, a 16-membered macrolide. The initial isolate was macrolide-susceptible, but the isolates after the treatment were resistant to 14 and 15-membered macrolides and had two amino acid (65WR66) deletions in ribosomal protein L4.
Bozdogan
B
B
Department of Pathology, Hershey Medical Center, Hershey, PA, USA.
Appelbaum
P C
PC
Ednie
L
L
Grivea
I N
IN
Syrogiannopoulos
G A
GA
D000595:Amino Acid Sequence; D000900:Anti-Bacterial Agents / Q000494:pharmacology* / Q000627:therapeutic use; D002648:Child; D017124:Conserved Sequence; D004269:DNA, Bacterial / Q000737:chemistry / Q000235:genetics; D024881:Drug Resistance, Bacterial / Q000235:genetics; D016521:Electrophoresis, Gel, Pulsed-Field; D006801:Humans; D008297:Male; D015644:Miocamycin / Q000494:pharmacology* / Q000627:therapeutic use; D008969:Molecular Sequence Data; D009154:Mutation; D010612:Pharyngitis / Q000188:drug therapy* / Q000382:microbiology; D012269:Ribosomal Proteins / Q000235:genetics*; D016415:Sequence Alignment; D013290:Streptococcal Infections / Q000188:drug therapy* / Q000382:microbiology*; D013297:Streptococcus pyogenes / Q000235:genetics*
D000900:Anti-Bacterial Agents; D004269:DNA, Bacterial; D012269:Ribosomal Proteins; C056368:ribosomal protein L4; D015644:Miocamycin